363 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1567)
- Addiction (14)
- Allergy, Asthma, & Immunology (11)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (26)
- Blood Disorders (37)
- Bone & Muscle (8)
- Cancer (639)
- Child Development (4)
- COVID-19 (Coronavirus) (28)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (13)
- Ear, Nose and Throat (5)
- Endocrine & Metabolic Disease (11)
- Eye (8)
- Gastrointestinal and Digestive Diseases (19)
- Hair and Skin Disorders (1)
- Headaches (5)
- Healthy Volunteers (131)
- Heart Disease (105)
- Infectious Disease (37)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (35)
- Lung Disease (29)
- Meniere's Disease (1)
- Neurological Disorders (131)
- Nutrition (3)
- Obesity (2)
- Obstetrics & Gynecology (40)
- Pain Management (1)
- Pediatrics (78)
- Psychiatric Disorders (57)
- Rehabilitation (7)
- Stroke (5)
- Surgery (7)
- Transplant (36)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 5 of 5
Condition: Valve Disease / Tricuspid Valve Disease
Investigator: Susheel Kodali, MD
Status: Closed
This is a prospective, single-arm, multi-center, early feasibility study. This research study is for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the heart's tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart…
Condition: Valve Disease / Tricuspid Valve Disease
Investigator: Susheel Kodali, MD
Status: Closed
This is a research study for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the hearts tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart has to pump more blood with each beat to push the same amount of blood forward.…
Condition: Liver Disease / NASH
Investigator: Julia Wattacheril, MD, MPH
Status: Closed
The Sponsor is conducting this study to find out how safe and effective the investigational drug (alsocalled a study drug) obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by NASH. Currently, there are no therapies approved for the treatment of NASH. OCA (the brand name is Ocaliva) has been approved in several…
Condition: Liver Disease / NASH
Investigator: Elizabeth Verna, MD
Status: Closed
This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. The main purpose of this research study is to collect and study information on patients with NAFLD/NASH.The goal of this study is to observe any treatment…
Condition: Liver Disease / NASH
Investigator: Elizabeth Verna, MD
Status: Closed
Patients who have been diagnosed with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis may be eligible to participate in this clinical trial. NASH is liver inflammation and damage caused by a buildup of fat in the liver. The main purpose of the study is to test the safety and efficacy of a drug called Emricasan (IDN-6556) in reducing the risk…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE